Cancer/Tumor Profiling Market Size, Growth | Industry Report, 2026

1. Welcome To Dataintelo

2. Cancer/Tumor Profiling Market Size, Growth | Industry Report, 2026 Global Cancer/Tumor Profiling Market was valued to reach USD 12.6 Billion in 2017. The market is projected to grow at CAGR of 8.5% over the forecast period 2020-2026, owing to factors like growing incidences of cancer across the globe, increasing utilization of biomarkers for tumor profiling and surge in cancer research and technological advancements in profiling.

3. Market Trends, Drivers, Restraints, and Opportunities: Increasing prevalence of cancer and growing usage of biomarkers in cancer profiling are expected to boost the growth of the market in the coming years. Increase in funding and research on cancer and technological advances are anticipated to propel market growth during the estimated timeframe. However, lack of capital investments and rise in technical problems related to sample storage and collection are likely to impede the growth of the market. Moreover, poor recompense scenario and short biomarker discovery to approval ratio are anticipated to hamper market growth. Rising demand for personalized medicines and point-of-care diagnostics is expected to offer numerous market growth opportunities.

4. Scope of the report: The report on cancer/tumor profiling market includes an assessment of the market, size, share, trends, segments and regional markets. Overview and dynamics have been included in the report

5. Cancer/Tumor Profiling Market Segment Insights: NGS associated advantages is attributed to enhance next-generation sequencing segment growth. In terms of technology, the cancer/tumor profiling market has been divided into immunoassays, in situ hybridization, mass spectrometry, polymerase chain reaction (PCR), microarrays, next-generation sequencing (NGS), and other technologies. The next-generation sequencing (NGS) segment is anticipated to expand at substantial growth pace during the forecast period due to its advantages such as effectively exploration of genetic alterations in a range of cancers. Moreover, it provides a number of differentially expressed gene and epigenetic variants, which aid in the development of new biomarkers for early diagnosis of cancer. Increasing number lung cancer cases is fueling the growth of the lung cancer segment Based on cancer types, the market has been segmented into breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, and other cancers. The lung cancer segment is estimated to expand at a significant CAGR during the forecast period owing to rise in the number lung cancer cases across the globe.

6. Growing utilization of cancer/tumor profiling in diagnostic centers is expected to boost the segment growth during the forecast period On the basis of applications, the market has been bifurcated into research applications clinical applications. The research applications segment is further categorized as biomarker discovery and personalized medicine. The clinical applications segment is divided into diagnostics, prognostics, monitoring & treatment, and screening. The research applications segment is projected to account for a considerable share of the market due to growing emphasis on biomarker detection for drug development and rising demand for custom-made medicines. Market in North America is estimated to witness significant growth over the coming years. In terms of geography, the global cancer/tumor profiling market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East &Africa. The market North America is anticipated to grow considerably in the coming years owing to rise in investment for the detection and research and development of biomarkers by molecular profiling and increase in the demand for tailored therapeutics.

7. Competitive Landscape: Major companies in the cancer/tumor profiling market include Caris Life Sciences, Foundation Medicine, Genomic Health Inc., Guardant Health, Inc., Helomics Corporation, HTG Molecular Diagnostics, Inc., Illumina, Inc., NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., QIAGEN N.V., Ribomed Biotechnologies, Inc., and Sysmex Corporation. They engage in numerous strategic initiatives such as mergers, agreements, product launches, acquisitions, collaborations, technological upgrade, and partnerships to gain maximum market share and sustain the competition in the market. Segments Covered in the Report The global cancer/tumor profiling market has been segmented based on technology, cancer types, biomarker types, applications, and regions

8. By Technology Immunoassays In Situ Hybridization Mass Spectrometry Microarrays Next-Generation Sequencing Polymerase Chain Reaction Other Technologies By Cancer Types Breast Cancer Colorectal Cancer Lung Cancer Melanoma Prostate Cancer Other Cancers By Biomarker Types Genetic Biomarkers Protein Biomarkers Other Biomarkers

9. By Applications • Research Applications • Biomarker Discovery • Personalized Medicine • Clinical Applications • Diagnostics • Prognostics • Monitoring & Treatment • Screening • By Regions         • North America • Europe • Asia Pacific • Latin America • Middle East & Africa

10. Thank You